SLC5A2 and diabetes mellitus: Since type 2 diabetes is diagnosed based on glycaemia levels, important changes over the last 15 years began with the emergence of multiple new anti-diabetes  therapies (DPP-4 inhibitors, GLP-1-receptor agonists, and SGLT2 inhibitors).